Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 157 clinical trials
Featured trial
Pacific 4: A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab with Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with unresected Stage I/II, lymph-node negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515)

This is a Phase III, randomized, placebo-controlled, double-blind, multi-center study assessing the efficacy and safety of durvalumab with SoC SBRT versus placebo with SoC SBRT in patients with unresected clinical Stage I/II lymph node-negative (T1 to T3N0M0) NSCLC.

  • 0 views
  • 26 Aug, 2022
  • 1 location
A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab With Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients With Unresected Stage I/II, Lymph-node Negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515) Osimertinib Following SBRT, a Single Arm Cohort for Patients With Unresected Stage I/II, Lymph Node Negative NSCLC Harboring a Sensitizing EGFR Mutation (PACIFIC-4)

This is a Phase III, randomized, placebo-controlled, double-blind, multi-center study assessing the efficacy and safety of durvalumab with SoC SBRT versus placebo with SoC SBRT in patients with unresected clinical Stage I/II lymph node-negative (T1 to T3N0M0) NSCLC. An additional cohort will assess Osimertinib following SBRT in patients with early …

durvalumab
EGFR
lung carcinoma
stereotactic body radiation therapy
osimertinib
  • 208 views
  • 28 Oct, 2022
  • 170 locations
Pancreatic Adenocarcinoma Neoadjuvant Combination Chemotherapy and Stereotactic Body Radiation Therapy Before Surgery

This is a single-arm, single-center feasibility trial of patients with borderline resectable pancreatic adenocarcinoma receiving radiation therapy with Stereotactic body radiation therapy (SBRT

  • 0 views
  • 04 Oct, 2022
  • 1 location
Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal Melanoma

This phase II trial studies how well stereotactic body radiation therapy and aflibercept work in treating patients with uveal melanoma. Stereotactic body radiation therapy is a specialized

Accepts healthy volunteers
  • 0 views
  • 07 Oct, 2022
  • 1 location
SBRT Combined With PD-1 Inhibitor and Thoracic Hyperthermia for Advanced NSCLC

The aim of this trial is to investigate the primary efficacy of SBRT combined with PD-1 inhibitor and thoracic hyperthermia in patients with EGFR, ALK, and ROS1 negative stage IV NSCLC patients who progressed after first-line treatment. At least one lesion (primary or metastatic) was selected for SBRT treatment, and …

  • 0 views
  • 07 Oct, 2022
  • 1 location
Phase II Trial of 18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation Therapy

> Eligibility People ages 18 and older with newly diagnosed prostate cancer who have no evidence of distant metastatic disease and plan to get stereotactic body radiation

  • 0 views
  • 27 Oct, 2022
  • 1 location
Clinical Trial Comparing Dose-intensified SBRT With Conventional Radiation Therapy for Spinal Metastases (DOSIS RCT)

This study will compare pain (primary end-point) and local metastatic tumor control (secondary end-point) after dose-intensified image-guided fractionated stereotactic body radiation therapy

  • 0 views
  • 23 Feb, 2022
SBRT Followed by Neoadjuvant Immunochemotherapy in Resectable Stage IB to III Non-small Cell Lung Cancer (SACTION01)

The purpose of this study is to find out the effectiveness stereotactic body radiation therapy (SBRT) followed by two cycles of Tislelizumab (PD-1 inhibitor) with chemotherapy as treatment for

EGFR
carcinoma
serum bilirubin level
pd-1 inhibitor
platelet count
  • 0 views
  • 30 May, 2022
  • 1 location
SBRT for Oligoprogressive NSCLC After Treatment With PD-1 Immune Checkpoint Inhibitors

Despite the impressive response rate to PD-1 immune checkpoint inhibitors, resistance inevitably develops in most patients. Stereotactic body radiation therapy (SBRT) plays a growing role in the

  • 0 views
  • 04 Mar, 2021
  • 1 location
Microwave Ablation With MRI-Guided SBRT Boost in Renal Cell Carcinoma

The specific aims of this study are: To determine the safety and feasibility of treating patients with a combination of MRI guided stereotactic body radiation therapy and microwave

carcinoma
metastasis
primary tumor
  • 6 views
  • 27 Jan, 2022
  • 1 location